Document:

Exhibit 10.18

 

REDEMPTION AGREEMENT

 

THIS REDEMPTION AGREEMENT
(this “Agreement”) is made effective as of June 3, 2020, by and among Nikola Corporation, a Delaware corporation
(f/k/a VectoIQ Acquisition Corp. (“VectoIQ”)) (the “Company”), and M&M Residual, LLC,
a Nevada limited liability company (“Holder”).

 

RECITALS

 

WHEREAS, the
Company entered into that certain Business Combination Agreement, dated March 2, 2020 (the “Business Combination
Agreement”), by and among VectoIQ, VCTIQ Merger Sub Corp., a wholly-owned subsidiary
of VectoIQ incorporated in the State of Delaware, and Nikola Subsidiary Corporation,
a Delaware corporation (f/k/a Nikola Corporation “Nikola”);

 

WHEREAS, at
the Effective Time under the Business Combination Agreement (as such term is defined therein) Holder is entitled to receive shares
of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) in exchange for the shares
of capital stock of Original Nikola held by Holder, and pursuant to Section 7.19 of the Business Combination Agreement, 7,000,000
shares out of the total shares issuable to Holder at the Effective Time (the “Redemption Shares”) shall be redeemed
by the Company immediately following, and subject
to, the Effective Time, at a purchase price of $10.00 per share; and

 

WHEREAS, Holder
desires to assign, convey, deliver, grant, sell and transfer the Redemption Shares to the Company for the Redemption Price (as
defined below), pursuant to the Business Combination Agreement.

 

NOW, THEREFORE,
in consideration of these premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:

 

1.            Redemption
of Stock.

 

1.1            Redemption.
Holder hereby agrees to assign, convey, deliver, grant, sell and transfer to the Company at the Closing (as defined below), and
the Company hereby agrees to accept, receive and redeem from Holder at the Closing, all of such Holder’s right, title and
interest of every nature in and to the Redemption Shares, for the aggregate redemption price of Seventy Million Dollars ($70,000,000)
(the “Redemption Price”).

 

2.            Closing;
Delivery.

 

2.1            Closing.
The closing of the redemption of the Redemption Shares (the “Closing”) shall take place remotely via the exchange
of documents and signatures immediately after and subject to the Effective Time (as defined in the Business Combination Agreement).

 

2.2            Deliveries.
At the Closing, the Company shall deliver to Holder the Redemption Price for the Redemption Shares by wire transfer of immediately
available funds to a bank account designated by Holder.

 

     

     

    

 

3.            Representations
and Warranties of Holder. Holder solely with respect to itself and the Redemption Shares, hereby represents and warrants
to the Company that the following representations are true and correct as of the date of the Closing.

 

3.1            Authorization.
Holder has full capacity, power and authority to enter into this Agreement and to transfer the Redemption Shares under this Agreement,
and Holder is not obligated to transfer the Redemption Shares to any other person or entity. This Agreement, when executed and
delivered by Holder and the other parties hereto, will constitute the valid and legally binding obligation of Holder, enforceable
in accordance with its terms. Holder, if other than a natural person, has been duly organized and is validly existing in good
standing under the laws of the jurisdiction of its organization as the type of entity it purports to be.

 

3.2            Compliance
with Other Instruments. The execution, delivery and performance by Holder of this Agreement and the performance of
Holder of its obligations hereunder will not result in any violation or be in conflict with or constitute, with or without the
passage of time and giving of notice, a default under any instrument, judgment, order, writ, decree, contract or agreement to
which Holder is a party or to which Holder or the Redemption Shares is otherwise subject.

 

3.3            Ownership
of Stock. Holder is the sole beneficial and record owner of, and has good and marketable title to, the Redemption Shares,
free and clear of any and all liens, security interests, claims or other encumbrances. Holder has full capacity, power and authority
to assign, convey, deliver, grant, sell and transfer absolute ownership of the Redemption Shares to the Company, and upon delivery
of the Certificates at the Closing, the Company will obtain good and marketable title to the Redemption Shares, free and clear
of any and all liens, security interests, claims or other encumbrances.

 

3.4            Sophisticated
Holder. Holder (a) is a sophisticated individual familiar with transactions similar to those contemplated by this Agreement,
(b) has adequate information concerning the business and financial condition of the Company to make an informed decision regarding
the sale of the Redemption Shares, (c) has been afforded the opportunity to ask questions of and request information from,
and has received satisfactory answers and information from, the Company and its representatives with respect to the Company and
its business, operations, assets, liabilities, prospects and financial condition as Holder deemed necessary to evaluate the merits
and risks of the sale of the Redemption Shares hereunder, and (d) has independently and without reliance upon the Company,
and based on such information and advice of business, financial, legal, tax and other advisors as Holder has deemed appropriate,
made its own analysis and decision to enter into this Agreement.

 

4.            Representations,
Warranties and Covenants of the Company. The Company hereby represents and warrants to each Holder that the following representations
are true and correct as of the date of the Closing and covenants as follows:

 

4.1            Organization,
Good Standing and Corporate Power. The Company is a corporation duly organized, validly existing and in good standing under
the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as presently conducted
and as proposed to be conducted.

 

    2

     

    

 

4.2            Authorization.
All corporate action required to be taken by the Company’s Board of Directors and stockholders in order to authorize the
Company to enter into this Agreement, and to redeem the Redemption Shares at the Closing, has been taken or will be taken prior
to the Closing. This Agreement, when executed and delivered by the Company, will constitute the valid and legally binding obligation
of the Company, enforceable against the Company in accordance with its terms.

 

4.3            Compliance
with Other Instruments. The execution, delivery and performance by the Company of this Agreement and the redemption
of the Redemption Shares will not result in any violation or be in conflict with or constitute, with or without the passage of
time and giving of notice, a default under any instrument, judgment, order, writ, decree, contract or agreement to which the Company
is a party or to which the Company or the Redemption Shares is otherwise subject.

 

5.            Survival
of Covenants and Warranties; Indemnification.

 

5.1            Unless
otherwise set forth in this Agreement, the covenants, representations and warranties of the parties contained in or made pursuant
to this Agreement shall survive the execution and delivery of this Agreement and the Closing and shall in no way be affected by
any investigation or knowledge of the subject matter thereof made by or on behalf of either party.

 

5.2            Each
party hereby agrees to hold harmless and indemnify the other party and such other party’s administrators, affiliates, agents,
beneficiaries, directors, employees, executors, heirs, legatees, officers, stockholders, other representatives, successors and
permitted assigns, as applicable, against any and all claims arising out of, relating to and/or resulting from any breach of or
default under any of the representations, warranties, covenants and other agreements of the indemnifying party set forth in this
Agreement.

 

6.            Miscellaneous.

 

6.1            Successors
and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective
successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other
than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or
by reason of this Agreement, except as expressly provided in this Agreement. Each Holder may not assign, whether voluntarily or
by operation of law, any of its rights and obligations under this Agreement, except with the prior written consent of the Company.

 

6.2            Governing
Law. This Agreement shall be governed by the internal law of the State of Delaware.

 

6.3            Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf) or
other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid
and effective for all purposes.

 

    3

     

    

 

6.4            Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement.

 

6.5            Notices.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively
given upon the earlier of actual receipt or: (a) personal delivery to the party to be notified, (b) when sent, if sent
by electronic mail or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then
on the recipient’s next business day, (c) five (5) days after having been sent by registered or certified mail,
return receipt requested, postage prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight
courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All communications shall
be sent to the respective parties at their address as set forth on the signature page, or to such e-mail address, facsimile number
or address as subsequently modified by written notice given in accordance with this Subsection 6.5. All notices and other
communications shall be sent to the addresses set forth on the signature pages attached hereto.

 

6.6            Amendments
and Waivers. Any term of this Agreement may be amended, terminated or waived only with the written consent of the Company
and Holder.

 

6.7            Severability.
The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other
provision.

 

6.8            Entire
Agreement. This Agreement (including the Exhibits hereto), constitutes the full and entire understanding and agreement
between the parties with respect to the subject matter hereof, and any other written or oral agreements relating to the subject
matter hereof existing between the parties are expressly canceled.

 

(Remainder of Page Intentionally
Left Blank)

 

    4

     

    

 

IN WITNESS WHEREOF,
the undersigned have executed this Redemption Agreement as of the date first written above.

 

	 	COMPANY:
	 	 
	 	NIKOLA CORPORATION
	 	 
	 	 
	 	By:	/s/ Mark A. Russell
	 	Name:	Mark A. Russell
	 	Title:	President and Chief
        Executive Officer

 

(Signature
Page to Redemption Agreement)

 

    

     

    

 

IN WITNESS WHEREOF,
the undersigned have executed this Redemption Agreement as of the date first written above.

 

	 	HOLDER:
	 	 
	 	M&M RESIDUAL, LLC
	 	 
	 	 
	 	By:	/s/ Trevor R. Milton
	 	Name:	Trevor R. Milton
	 	Title:	Member

 

(Signature
Page to Redemption Agreement)

 

    

     

    

 

EXHIBIT A

 

STOCK

 

	Series of Stock	Number of Shares	Price Per Share	Total Price
	Common Stock	7,000,000	$10.00	$70,000,000
	Total	7,000,000	$10.00	$70,000,000Laboratory
Services AGreement

 

This
Laboratory Services Agreement (“Agreement”) is made and entered into as of May 15, 2020 (“Effective Date”)
by and between Cellular Technology Limited, an Ohio limited liability company organized under the laws of Ohio, with its principal
place of business located at 20521 Chagrin Boulevard, Shaker Heights, Ohio 44122 (“CTL”), and Generex Biotechnology
Corporation, a public company organized under the laws of Delaware , with its principal place of business located at 10102 USA
Today Way, Miramar, FL 33025 (“Company”). CTL and the Company are each referred to herein individually as a “Party”
and collectively as the “Parties.”

 

Recitals

WHEREAS,
Company desires to retain the services of CTL from time to time to perform certain high throughput immune monitoring laboratory
services and Laboratory desires to provide such services.; and

WHEREAS,
CTL desires to provide such services under the terms and conditions of this Agreement and any attached exhibits.

NOW,
THEREFORE, in consideration of the promises and mutual covenants herein contained, and other valuable consideration, the Parties
agree as follows:

1.       DEFINITIONS

1.1       “Confidential
Information” is defined in Section 8.1.

1.2       “Good
Laboratory Practices” means the practices and procedures set forth in Title 21, United States Code of Federal Regulations,
Part 58, and any other regulations, guidelines or guidance documents relating to good laboratory practices.

1.3       “Inventions”
is defined in Section 5.1.

1.4       “Materials”
means any tangible materials provided by Company to CTL under this Agreement or any SOW, including ______________________________________________________________________.

1.5       “Person”
means any person or entity, including any individual, trustee, corporation, partnership, trust, unincorporated organization, limited
liability company, business association, firm, joint venture or governmental agency or authority.

1.6       “Records”
is defined in Section 4.1.1.

1.7       “Reports”
means any reports or documentation prepared by CTL pursuant to Section 2.3.

1.8       “Services”
means the services to be performed by CTL under this Agreement, including the testing and analysis of Materials and the generation
and delivery of any Reports, as further defined from time to time in a SOW.

1.9       “SOW”
is defined in Section 2.1.1.

1.10       “Third
Party” means any Person other than a Party to this Agreement.

2.       Statements
of Work; Performance of Services; RePorts

2.1       Statements
of Work.

 

a).All
Services to be performed under this Agreement are set forth in a Statement of Work (“SOW”), attached hereto
as Appendix A. This Agreement, together with each individual SOW (including any attachments or schedules thereto), but
separate and apart from any other SOW, shall constitute the entire agreement between the Parties for the performance of any Services
defined in the applicable SOW.

 

b).       The
performance of all Services shall be controlled by the terms and conditions of this Agreement (including any applicable SOW).
The terms and conditions of any business forms used by CTL for purposes of invoicing, delivering Reports, or otherwise shall not
form part of this Agreement unless otherwise stated in an applicable SOW. In the event of a conflict between the terms and conditions
of this Agreement and any SOW, the terms and conditions of the Applicable SOW shall control.

2.2       Performance
of Services.

a).       CTL
shall perform the Services in accordance with the terms and conditions of this Agreement and the applicable SOW.

b).The
Services shall, unless otherwise specified in the applicable SOW, be conducted in compliance with Good Laboratory Practices and
shall use such personnel, methods, procedures and resources specified in the applicable SOW. All Services shall be conducted in
a professional and competent manner, in compliance with all applicable laws, ordinances, rules, regulations and guidelines. 

c).       In
the event of a material error by CTL in the performance of the Services, upon Company’s request to do so, CTL will conduct
again, at its own cost and within a reasonable period of time, that part of the work affected by such error.

2.3       Reports.
CTL shall prepare and deliver to Company in a timely fashion, all reports and other documentation required under a SOW.

3.       Payments

3.1       Costs.
In compensation for the Service, Company shall pay CTL the fees and costs in the amounts and in accordance with the terms, conditions
and payment schedules as set forth in the applicable SOW.

3.2       Invoicing.
Once each calendar month, or as Services are rendered, CTL shall submit to Company a written invoice detailing the amounts due
to CTL for the performance of the Services detailed in a SOW. Unless otherwise specified in the applicable SOW, invoices shall
be sent to Company via e-mail at the following addresses:

jterrell@generex.com

 

 

3.3       Payment.
Within thirty (30) days of receipt of an invoice issued pursuant to Section 3.2, Company shall pay to CTL the invoiced
amount. Payment shall be made in United States currency by check or wire transfer sent as directed by CTL.

3.4       Change
in Scope of Services. Any change in the scope of Services which impacts the cost for Services rendered under this Agreement
and applicable SOW shall require a written change order or similar document signed by both CTL and the Company. Unless otherwise
agreed, any increase or reduction in total cost associated with a change in scope shall be established based upon the fee structure
set forth in the applicable SOW.

3.5       Acceleration
of Schedule. If the Company or the sponsor later desire CTL to accelerate the schedule for any of the Services, CTL will attempt
to find a mutually agreeable modification of the schedule to accommodate the Company’s and/or the sponsor’s request.
However, CTL’s ability to meet such a request may depend upon the complexity of Services involved, the volume of work requested,
the availability of materials and/or personnel needed to meet the request, and the time frame involved. An acceleration of the
specified dates outlined in the Agreement or applicable SOW may result in accelerated services surcharges based upon the aforementioned
factors.

 

4.       Record
Keeping; Inspections

4.1       Records.

a).       CTL
shall maintain complete and accurate records, in appropriate detail for patent and regulatory purposes, fully and properly reflecting
all Services performed by it and the results thereof, including, without limitation, such data and materials as are required to
be maintained pursuant to any applicable law, ordinance, rule, regulation or guideline, Good Laboratory Practices, and any applicable
SOW (“Records”).

b).       To
the extent practical, all Records shall be kept separately from documentation and materials associated with other CTL laboratory
activities.

c).       CTL
shall maintain the Records for two (2) years after CTL’s completion of Services under the applicable SOW or such other longer
amount of time as is required by applicable law or the applicable SOW. Prior to destroying any Records, Laboratory shall give
Company at least thirty (30) days prior written notice of CTL’s intention to destroy such. Upon Company’s written
request, and at Company’s expense, Laboratory shall deliver to Company all original Records.

d).       All
Records shall be the sole property of Company and shall not be used by CTL for any purpose other than performing the Services
or as otherwise required by this Agreement or applicable Work Order.

4.2       Inspections
and Right to Audit.

a).CTL
agrees to promptly notify Company of any government or regulatory inspection or audit of CTL that may impact or relate to the
Services, Materials or Records. CTL shall inform Company of the results such governmental or regulatory agency inspection or audit
and shall promptly take any reasonable steps required to cure any deficiencies shown as a result of such audit or inspection.

 

b).       During
the period of time in which CTL is providing Services and until the end of the period time in which CTL is maintaining the Records,
Company may upon reasonable written notice to CTL, visit during normal business hours CTL’s facilities where Services have
been or are being performed to: (i) inspect and audit the facilities; and (ii) review, copy and inspect all Records pertaining
to the Services and any CTL standard operating services pertinent to the providing of the Services. All representatives of or
on behalf of Company who visit, inspect or audit CTL’s facilities shall be subject to and bound by the terms of any confidentiality
agreements between the Parties.

5.       Ownership;
Intellectual Property

5.1Ownership
Generally.The Parties acknowledge and agree that the existing inventions and technologies of each of CTL and Company
are their separate property, respectively, and are not affected by this Agreement and neither Party shall have any claims to or
rights in such existing inventions and technologies of the other party.

5.2.       Company’s
Property; Inventions. Subject to subsection 5.3, Company shall solely own (and CTL hereby assigns to Company) all right, title
and interest in and to all intellectual property created or arising in connection with, or related to, the Materials, the performance
of any Services or the preparation of any Reports or Records regardless of whether such intellectual property was conceived, reduced
to practice or otherwise created or authored solely by CTL or jointly by CTL and Company or a Third Party (“Inventions”).
CTL shall promptly disclose to Company all Inventions. If any part of the Services or Inventions cannot be fully exploited without
violating intellectual property rights owned or licensed by CTL and not assigned hereunder, CTL hereby grants Company a perpetual,
irrevocable, worldwide, royalty-free, non-exclusive, license to fully exploit and exercise all such intellectual property rights.

5.3.       CTL’s
Property. Notwithstanding the provisions of subsection 5.3 above, CTL’s Property shall remain the sole and exclusive
property of CTL, and such CTL Property shall not be deemed to constitute Inventions. “CTL’s Property” means
any intellectual property which has been created by or in the possession of CTL prior to the date of this Agreement and all subsequent
(i) inventions (whether or not patentable), know-how, works of authorship, technology, software, techniques, developments, ideas,
concepts, discoveries, designs, algorithms, models, formulations, improvements, protocols, data and proprietary information; and
(ii) patents, copyrights, trademarks, service marks, trade secrets, or other intellectual property rights associated with the
foregoing, which (A) is an improvement, modification or development of CTL’s equipment, assays, materials, laboratory testing,
data collection or data management processes, procedures, or methods (whether or not created, developed or produced pursuant to
this Agreement), and (B) does not contain any, or is not developed using any Company Property. 

5.4       Retained
Rights. No rights are granted to CTL under any intellectual property owned or controlled by Company, except to the extent
strictly necessary to allow CTL to perform the Services and fulfill its obligations under this Agreement. Upon completion of such
Services or fulfillment of such obligations, or expiration or termination of this Agreement, the limited rights granted to Laboratory
under this Section 5.4 shall immediately terminate.

6.       REPRESENTATIONS;
Disclaimers

6.1       CTL
Representations. CTL hereby represents and warrants to Company that:

a).       
CTL has the full right, power and authority, and has obtained all approvals, permits or consents necessary, to enter into this
Agreement and to perform all of its obligations hereunder.

b).       CTL
has not, prior to the Effective Date, entered into and shall not, following the Effective Date, enter into any agreement and has
not granted any now existing, or agreed to grant any future, license, right or privilege which agreement, license, right or privilege
conflicts in any way with this Agreement or CTL’s obligations hereunder.

6.2       Company’s
Representations. Company hereby represents and warrants to CTL that:

a).       Company
has the full right, power and authority, and has obtained all approvals, permits or consents necessary, to enter into this Agreement
and to perform all of its obligations hereunder.

b).       Company
has not, prior to the Effective Date, entered into and shall not, following the Effective Date, enter into any agreement and has
not granted any now existing, or agreed to grant any future, license, right or privilege which agreement, license, right or privilege
conflicts in any way with this Agreement or Company’s obligations hereunder.

c).       Company
represents that it owns or has the right to use all copyright, trademark, patents, and other intellectual property rights to the
Confidential Information (including any Materials) supplied by Company to CTL and that such do not infringe upon any third party’s
patents, trade secrets, copyrights or other intellectual property rights.

6.3       
Disclaimer. EXCEPT AS OTHERWISE PROVIDED IN SECTION 6.2 ABOVE, THE CONFIDENTIAL INFORMATION (INCLUDING ANY MATERIALS) SUPPLIED
BY COMPANY TO CTL IS BEING SUPPLIED “AS IS” AND COMPANY MAKES NO WARRANTIES WITH REGARD THERETO, AND DISCLAIMS ALL
IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, AND FITNESS FOR A PARTICULAR PURPOSE.

7.       INDEMNIFICATION

7.1       General
Indemnification. CTL and Company (each, respectively, being the “Indemnifying Party”) shall protect, defend, indemnify,
and save harmless each other , and their respective Affiliates and their respective officers, directors, employees, and agents
(the “Indemnified Party”) from and against any and all claims, losses, demands, causes of action, and any and all
related costs and expenses of every kind (including, but not limited to, reasonable attorneys’ fees, costs, and expenses
suffered by the parties hereto and/or their employees, and/or suffered by any other person or entity) on account of (i) personal
injury, death, or damage to property occurring, growing out of, incident to, or resulting directly or indirectly from, but only
to the extent of, the negligence or willful misconduct of the Indemnifying Party, its agents, representatives, employees, and/or
Subcontractors, and (ii) a breach by the Indemnifying Party or any subcontractor of any of its representations, warranties, covenants,
agreements or obligations under this Agreement or any SOW.

7.2       Defense;
Selection of Counsel. The Indemnifying Party shall have the right to select defense counsel and to direct the defense or settlement
of any such Claim. The Indemnifying Party shall promptly provide the Indemnified Party with reasonable written notice of any Claim.
The Indemnified party shall reasonably cooperate with the Indemnifying party and its legal representatives in the investigation
and defense of any claim. The Indemnified Party may obtain representation by separate legal counsel, at its own expense.

7.3       Survival
of Obligations. The terms of this Section 7 and the Parties’ obligations hereunder, shall survive the ttermination or
expiration of this Agreement.

 

8.       Confidential
Information

8.1       Confidentiality
of Information. During the course of performing Services, CTL may receive, or have access to confidential information of Company
and Company might receive or have access to confidential information of Laboratory. Such confidential Information includes, but
is not limited to, the following: Materials; Records; Reports; Inventions; CTL’s equipment, assays, and materials; CTL’s
laboratory testing processes, procedures, or methods; and CTL’s data collection or data management processes, procedures,
or methods. (“Confidential Information”) Each Party receiving (the “Receiving Party”) Confidential Information
of the other party (the “Disclosing Party”) agrees to hold in strict confidence the Disclosing Party’s Confidential
Information.

 

8.2       Use
of Confidential Information. The Receiving Party will use the Disclosing Party’s Confidential Information only for the
purpose of fulfilling its obligations and exercising its rights under this Agreement and will not disclose it, without the prior
written consent of the Disclosing Party, to any third party except to the Receiving Party’s employees or agents who have
a need to know such information and are bound in writing by obligations of confidentiality and restrict use that protect Confidential
Information and that are at least as stringent as those provided herein. The obligations of confidentiality hereunder shall continue
for a period of ten (10) years from the later of the (i) expiration or early termination of the Agreement, or (ii) date of completion
or early termination of the Services. Such obligations shall not apply to information that the Receiving Party can establish:

a)       was
in the public domain at the time of disclosure;

b)       is
in the public domain, by publication or otherwise, after disclosure or development through no fault of the Receiving Party, its
agents or employees;

c)       was
already in the possession of the Receiving Party at the time of disclosure or development, as established by its contemporaneous
written records;

d)       was
independently developed by the Receiving Party without use of or reliance on any Confidential Information; or

e)       is
required to be disclosed by any law, rule, regulation, court order or other legal obligation provided that the Receiving Party
promptly provides written notice to the Disclosing Party of its notice of any such disclosure requirement to provide the Disclosing
Party the opportunity to seek a protective order or other appropriate remedy.

 

8.3       Publicity.
CTL shall not issue any press release or other publicity materials, or make any public presentation or representation with respect
to the existence of, or any of the terms or conditions of, this Agreement without the prior written consent of Company.

8.4       Availability
of Injunctive Relief. Each Party acknowledges that the disclosure of Confidential Information without the other Party’s
express written permission may cause irreparable harm, and that the breach or threatened breach of the non-disclosure and/or non-use
provisions of this Agreement will entitle the other party to injunctive relief, in addition to any other legal or equitable remedies
that may be available to it.

8.5       Data
Protection. All Confidential Information containing personal data and information shall be handled by CTL in accordance with
all applicable laws and regulation, including if applicable any patient privacy requirements.

 

9.       
TERM AND TERMINATION

9.1       Term.
The term of this Agreement (the “Term”) shall commence on the Effective Date and, unless sooner terminated
by mutual agreement or pursuant to any other provision of this Agreement, shall terminate five (5) years from the Effective Date.

9.2       Default.
Either Party may terminate this Agreement for any material breach by the other Party, provided that the terminating Party gives
the breaching Party written notice of such breach and the breach remains uncured after the expiration of thirty (30) days after
such written notice was given.

9.3       Effect
of Termination or Expiration. Termination or expiration of this Agreement through any means and for any reason shall not relieve
the Parties of any obligation accruing prior thereto and shall be without prejudice to the rights and remedies of either Party
with respect to any antecedent breach of any of the provisions of this Agreement.

9.4       Survival.
Sections 3, 4, 5, 6, 7, and 8 shall survive expiration or termination of this Agreement for any reason.

 

10.LIMITATION
OF DAMGAGES

 

UNDER
NO CIRCUMSTANCES SHALL EITHER PARTY BE ENTITLED TO, NOR SHALL EITHER PARTY BE RESPONSIBLE FOR, ANY INCIDENTAL, INDIRECT, CONSEQUENTIAL
OR SPECIAL DAMAGES (INCLUDING WITHOUT LIMITATION, LOSS OF PROFITS) ARISING IN CONNECTION WITH ANY DEFAULT OR BREACH OF OBLIGATIONS
UNDER THIS AGREEMENT OR ANY DOCUMENTS RELATED HERETO.

 

 

11.NOTICES

 

The
term “notice” as used throughout this Agreement shall mean written notice, except where specifically provided to the
contrary. Notice shall be delivered to the parties addressed below by (i) certified mail, return receipt requested (or the equivalent),
(ii) hand delivery with receipt acknowledged, or (iii) overnight courier service that provides a delivery receipt to the following
addresses or to such other address or person as a party may specify by notice given in accordance with this Section.

 

If
to Company:Generex Biotechnology Corporation

10102
USA Today Way

Miramar,
FL 33025Attention: Jason Terrell, MD, Chief Medical Officer

jterrell@generex.com

 

with
copies to:

 

rpurcell@nugenerex.com

mwernicke@nugenerex.com

 

If
to CTL:

 

Cellular
Technology Limited:

Magdalena
Tary-Lehmann, M.D., Ph.D.

Chief
Scientific Officer

Cellular
Technology Limited

20521
Chagrin Boulevard

Shaker
Heights, Ohio 44122

Telephone:
(216) 791-5084 ext. 124

FAX:       (216)
791-8814

E
mail:magda.tary-lehmann@immunospot.com

 

 

Notice
given in accordance with this Section shall be deemed delivered (i) when received, or (ii) upon refusal of receipt.

 

12       MISCELLANEOUS

12.1       
Independent Contractors. CTL and Company are independent contractors and are not, and shall not represent themselves as,
principal and agent or as a joint venture. Nothing herein shall create any association, partnership, joint venture, fiduciary
duty or the relation of principal and agent between the Parties hereto, and neither Party shall have the authority to assume or
create any obligations or responsibilities, expressed or implied, of the other or the other’s representatives in any way.
The employees and agents of each Party are not the employees or agents of the other Party.

12.2       
Force Majeure. Neither Party will be liable hereunder by reason of any failure or delay in the performance of its obligations
hereunder on account of strikes, shortages, riots, insurrection, fires, flood, storm, explosions, acts of God, war, governmental
action, labor conditions, earthquakes, or any other similar cause which is beyond the reasonable control of such party; provided,
however, that the Party affected shall promptly notify the other of the force majeure condition and to resume performance of its
obligations as soon as reasonably possible.

 

	12.3	Waiver.
                                         The failure of either Party to require performance by the other Party of any provision
                                         of this Agreement will not affect the full right to require such performance at any time
                                         thereafter nor will the waiver by either Party of a breach of any provision of this Agreement
                                         be taken or held to be a waiver of the provision itself.

 

12.4       
Severability. If any provision of this Agreement is found to be unenforceable, illegal or invalid under any applicable
law by a court of competent jurisdiction, such unenforceability, illegality or invalidity will not render this Agreement unenforceable,
illegal or invalid as a whole, and shall not affect the validity or enforceability of any other provision of this Agreement. The
Parties shall make a good faith effort to substitute a valid, legal and enforceable provision that reflects the intent of such
invalid, illegal or unenforceable provision and implements the purpose of the provision.

 

	

12.5	Governing
                                         Law. This Agreement shall be governed and construed in accordance with the laws of
                                         the State of Delaware, U.S.A., without regard to conflicts of law.

 

	12.6	Headings.
                                         The section headings appearing in this Agreement are inserted only as a matter of convenience
                                         and in no way define, limit, construe or describe the scope or extent of such section
                                         and in no manner affect this Agreement.

 

12.7       Authority.
Each Party warrants that it has full power and authority to enter into and perform its obligations under this Agreement, (ii)
this Agreement has been duly authorized by and is binding and enforceable upon such Party and (iii) the person signing this Agreement
on that Party's behalf has been duly authorized and empowered to enter into this Agreement. Each Party further acknowledges that
it has read this Agreement, understands it, and agrees to be bound by it.

 

 

12.8       
Counterparts. This Agreement may be signed in counterparts each of which shall be deemed to be original, but which together
will form a single agreement as if both parties had executed the same document.

 

12.9       Assignment.
Neither Party may not assign any of its rights or delegate any of its obligations under this Agreement without the express
written consent of the other Party, which consent may be unreasonably withheld. No permitted assignment will relieve either Party
of its liability for obligations under this Agreement.

 

12.10.
       Entire Agreement. This Agreement sets forth the entire understanding and agreement
of the parties as to the matters covered hereby. This Agreement supersedes any prior or collateral agreements with respect to
the matters covered by this Agreement.

 

12.11       
Binding Effect. This Agreement shall be binding upon, inure to the benefit of, and be enforceable by CTL and Company, and
their respective affiliates, successors, heirs, executors administrators, and permitted assigns

 

	12.12	Amendments.
                                         This Agreement may only be amended in a writing signed by duly authorized representatives
                                         of CTL and Company.

 

 

INTENDING
TO BE LEGALLY BOUND, the Parties have executed this Agreement by their duly authorized representative.

	CTL	 	Company
	 	 	 
	/s/ Madalena Tarey-Lehmann	By:  	/s/ Joe Moscato
	Magdalena Tary-Lehmann, M.D., Ph.D.	Print Name:  	Joe Moscato
	Chief Scientific Officer	Title:  	President & Chief Executive Officer
	 	 	 

 

    	 

    	 

    

APPENDIX
A- Statement of Work

 

This
Statement of Work (“SOW”), dated and effective ___________, 20____, submitted in connection with the Laboratory
Services Agreement by and between Cellular Technology Limited (“CTL”) and __________________________________________
(“Company”) dated _____________, 20___ (“Agreement”), is hereby agreed to by the Parties.

Pursuant
to Article 2 of the Agreement, this SOW (including any attachments hereto) shall be governed by the terms and conditions of the
Agreement and, if applicable, any modifications to the Agreement agreed to by the Parties and set forth in this SOW under the
section below, entitled “Modifications to Agreement.” Any such modifications shall apply only to this SOW, and
not to any previous or subsequent SOWs, unless expressly stated otherwise in such other SOW.

	CTL	 	Company
	 	 	 
	/s/ Madalena Tarey-Lehmann	By:  	/s/ Joe Moscato
	Magdalena Tary-Lehmann, M.D., Ph.D.	Print Name:  	Joe Moscato
	Chief Scientific Officer	Title:  	President & Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]